Amplatzer left atrial appendage occlusion: single center 10-year experience

Nietlispach, Fabian; Gloekler, Steffen; Krause, René; Shakir, Samera; Schmid, Michael; Khattab, Ahmed A.; Wenaweser, Peter; Windecker, Stephan; Meier, Bernhard (2013). Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheterization and cardiovascular interventions, 82(2), pp. 283-289. Wiley-Blackwell 10.1002/ccd.24872

Text ccd24872.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (275kB) | Request a copy

OBJECTIVES

To report a 10-year single center experience with Amplatzer devices for left atrial appendage (LAA) occlusion.

BACKGROUND

Intermediate-term outcome data following LAA occlusion are scarce.

METHODS

Short- and intermediate-term outcomes of patients who underwent LAA occlusion were assessed. All procedures were performed under local aesthesia without transesophageal echocardiography. Patients were discharged on acetylsalicylic acid and clopidogrel for 1-6 months.

RESULTS

LAA occlusion was attempted in 152 patients (105 males, age 72 ± 10 years, CHA2 DS2 -Vasc-score 3.4 ± 1.7, HAS-BLED-score 2.4 ± 1.2). Nondedicated devices were used in 32 patients (21%, ND group) and dedicated Amplatzer Cardiac Plugs were used in 120 patients (79%, ACP group). A patent foramen ovale or atrial septal defect was used for left atrial access and closed at the end of LAA occlusion in 40 patients. The short-term safety endpoints (procedural complications, bleeds) occurred in 15 (9.8%) and the efficacy endpoints (death, stroke, systemic embolization) in 0 patients. Device embolization occurred more frequently in the ND as compared to the ACP group (5 patients or 12% vs. 2 patients or 2%). Mean intermediate-term follow up of the study population was 32 months (range 1-120). Late deaths occurred in 15 patients (5 cardiovascular, 7 noncardiac, 3 unexplained). Neurologic events occurred in 2, peripheral embolism in 1, and major bleeding in 4 patients. The composite efficacy and safety endpoint occurred in 7% and 12% of patients.

CONCLUSION

LAA closure may be a good alternative to oral anticoagulation. This hypothesis needs to be tested in a randomized clinical trial to ensure that all potential biases of this observational study are accounted for.

Interest & Impact

Downloads

8 since deposited on 24 Mar 2014
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item